Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014456 | 0.93 | MAPT (0.68) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL12210768 | 0.87 | MAPT (0.60) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL15923825 | 0.83 | MAPT (0.56) | MAPTLMNAALDH1A1NPC1RAB9A | |
| Diethylamine SCHEMBL2890896 | 0.83 | MAPT (0.59) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL25666819 | 0.81 | MAPT (0.64) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL29739619 | 0.81 | MAPT (0.64) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL607025 | 0.81 | MAPT (0.67) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL26086348 | 0.80 | MAPT (0.51) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL2338671 | 0.79 | TDP1 (0.50) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL30380932 | 0.78 | CHRNB2 (0.58) | MAPTLMNAALDH1A1TDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286197-A1 | Carboxamide Derivatives As Therapeutic Agents | TRANSTECH PHARMA, INC. | 2010-11-11 | — | — | US | disclosed |
| US-7776919-B2 | Carboxamide derivatives as therapeutic agents | TransTech Pharm, Inc. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7423177-B2 | Carboxamide derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080119512-A1 | Carboxamide Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1377295-A4 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1377295-A2 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20020193432-A1 | Carboxamide derivatives as therapeutic agents | VTVX HOLDINGS I LLC | 2002-12-19 | — | — | US | disclosed |
| WO-2002070473-A2 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286197-A1 | Carboxamide Derivatives As Therapeutic Agents | AGER, S100B, S100A4 | MAPT 655/4885LMNA 373/4885ALDH1A1 2785/4885 |
| US-20020193432-A1 | Carboxamide derivatives as therapeutic agents | AGER, S100B, S100A4 | MAPT 624/4885LMNA 431/4885ALDH1A1 2802/4885 |
| US-20080119512-A1 | Carboxamide Derivatives as Therapeutic Agents | AGER, S100B, S100A4 | MAPT 655/4885LMNA 373/4885ALDH1A1 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.